Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2010
09/22/2010CN101837133A Gram positive microbes DNA vaccine and construction and application thereof
09/22/2010CN101837132A HN1 strain gB gene and avian 1L-18 gene combined nucleic acid vaccine of avian infectious laryngotracheitis virus and preparation method thereof
09/22/2010CN101837124A Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
09/22/2010CN101837123A Tumor cell vaccine and preparation method thereof
09/22/2010CN101837122A Genetic engineering composite peptide vaccine for inhibiting tumor angiogenesis and use thereof
09/22/2010CN101837117A Application of B cell epitope peptide from tetanus exotoxin fragment C
09/22/2010CN101234089B Alkaline fibroblast growth factor liposome vaccine and preparation method and application thereof
09/21/2010USRE41745 Vector; genetic vaccines for humans or horses; side effect reduction; increasing the protectiveness of a vaccinia-based vaccine
09/21/2010US7799902 Receptor coupling agents and compositions thereof
09/21/2010US7799900 humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases; treatment of B-cell associated diseases
09/21/2010US7799898 Human transferase family members and uses thereof
09/21/2010US7799762 Functionally substituted amino acids, having fatty acid chains bound through amidification of the amine functional groups of dipeptide like compounds, one end bears a functional side chain and other side neutral or charged acid
09/21/2010US7799759 albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins
09/21/2010US7799755 Stimulating a Th2 response by administering multivalent LNFPIII, an immunomodulatory glycan Lacto-N-Fucopentaose III, which contains the Lewis X trisaccharide (CD!%/antigen/); autoimmune disease; antidiabetic agents; antiarthritic agents; multiple sclerosis; colitis; psoriasis
09/21/2010US7799350 Treating peripherial blood mononuclear cells with a suppressive composition for a time sufficient to induce T cell tolerance; and introducing said cells to said patient.
09/21/2010US7799330 comprises claimed amino acid sequence or an immunogenic fragment thereof wherein the protein elicits production of antibodies that interfere with invasion by Babesia bovis into erythrocytes
09/21/2010US7799329 Viruses for the treatment of cellular proliferative disorders
09/21/2010US7799327 Employing nonimmunogenic blood products from patients with autoimmune disease
09/21/2010CA2445068C Azo compounds for type i phototherapy
09/21/2010CA2429672C Use of a pure allergen component
09/21/2010CA2416650C Enhancement of the action of central and peripheral nervous system agents
09/21/2010CA2370493C Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof
09/21/2010CA2369292C Method of modulating the activity of functional immune molecules
09/21/2010CA2345659C Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
09/21/2010CA2343074C Akt nucleic acids, polypeptides, and uses thereof
09/21/2010CA2330241C Attenuated pestiviruses
09/21/2010CA2327835C Methods and modified cells for the treatment of cancer
09/21/2010CA2327353C Structural proteins of fish pancreatic disease virus and uses thereof
09/21/2010CA2234941C Delivery of biologically active polypeptides
09/21/2010CA2225788C Therapeutic agents and autoimmune diseases
09/21/2010CA2225675C Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
09/21/2010CA2211578C Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
09/21/2010CA2192694C Cloning and expression of an acetylcholine-gated ion channel receptor subunit
09/17/2010CA2658714A1 Hcv-derived polypeptides and uses thereof
09/16/2010WO2010105251A2 Non-integrating retroviral vector vaccines
09/16/2010WO2010105128A2 A pkn3/rhoc macromolecular complex and methods of use therefor
09/16/2010WO2010104961A1 Treatment methods for autoimmune disorders
09/16/2010WO2010104959A1 Treatment and diagnostic methods for hypersensitive disorders
09/16/2010WO2010104949A2 Anti-bcma antibodies
09/16/2010WO2010104761A2 Anti-cd40 antibodies and uses thereof
09/16/2010WO2010104749A2 Antigen presenting cell targeted cancer vaccines
09/16/2010WO2010104748A2 Antigen presenting cell targeted anti-viral vaccines
09/16/2010WO2010104747A2 Antigen presenting cell targeted vaccines
09/16/2010WO2010104208A1 Generation, expression and characterization of the humanized k33n monoclonal antibody
09/16/2010WO2010104052A1 Humanized pcrv antibody having anti-pseudomonal activity
09/16/2010WO2010103488A1 Dengue virus-like particle and uses thereof
09/16/2010WO2010103284A1 Diagnosis and treatment of cell proliferation and differentiation disorders based on the fmn2 gene
09/16/2010WO2010103274A1 Antibody molecules having binding specificity for human il-13
09/16/2010WO2010103118A1 Chemotherapeutic composition for the treatment of cancer
09/16/2010WO2010103022A2 Oil-in-water adjuvanted influenza vaccine
09/16/2010WO2010102822A1 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
09/16/2010WO2010102792A2 Human antibodies against human fas and their use
09/16/2010WO2010085648A3 Methods for reducing radiation-induced tissue damage
09/16/2010WO2010075491A3 Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
09/16/2010WO2010067202A3 Mixing lyophilised meningococcal vaccines with non-hib vaccines
09/16/2010WO2010067201A3 MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
09/16/2010WO2010059689A3 Rsv f vlps and methods of manufacture and use thereof
09/16/2010WO2010056981A3 Methods and compositions for regulating iron homeostasis by modulation bmp-6
09/16/2010WO2010056910A3 Methods of treating cardiovascular disorders
09/16/2010WO2010054265A3 Monoclonal antibodies to fibroblast growth factor receptor 2
09/16/2010WO2010048588A3 Directed engagement of activating fc receptors
09/16/2010WO2010039224A3 Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
09/16/2010WO2010033587A3 Methods for treating progressive multiple sclerosis
09/16/2010WO2010005566A3 Notch-binding agents and antagonists and methods of use thereof
09/16/2010US20100235931 Novel Neurological Function of mPKCI
09/16/2010US20100235929 Compositions and Methods for Producing Antibodies Having Human Idiotypes in Transgenic Birds
09/16/2010US20100234300 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically
09/16/2010US20100233819 Robo: a novel family of polypeptides and nucleic acids
09/16/2010US20100233785 Novel methods and interferon deficient substrates for the propagation of viruses
09/16/2010US20100233690 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
09/16/2010US20100233267 Composite hydrogel
09/16/2010US20100233264 TEMPERATURE AND pH-SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT SAFTY IN VIVO AND HYDROGEL AND DRUG DELIVERY SYSTEM USING THEREOF
09/16/2010US20100233251 Vaccine Nanotechnology
09/16/2010US20100233250 Vaccine
09/16/2010US20100233249 Contraceptive methods and compositions related to proteasomal interference
09/16/2010US20100233238 Medical Devices Having Nanoporous Coatings for Controlled Therapeutic Agent Delivery
09/16/2010US20100233226 Drug-eluting nanowire array
09/16/2010US20100233215 IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
09/16/2010US20100233214 Extracellular matrix cancer vaccine adjuvant
09/16/2010US20100233213 Recombinant BCG Strains with Enhanced Ability to Escape the Endosome
09/16/2010US20100233212 Methods and compositions using listeria for enhancing immunogenicity by prime boost
09/16/2010US20100233211 Attenuated francisella and methods of use
09/16/2010US20100233210 Subgenomic replicons of the flavivirus dengue
09/16/2010US20100233209 Chikungunya virus infectious clones and uses therefor
09/16/2010US20100233208 Methods of Treating and Preventing Neurological Symptoms Caused by Avian Reovirus and Novel Associated Characteristics
09/16/2010US20100233207 C-glycolipids with enhanced th-1 profile
09/16/2010US20100233206 Marek's Disease Virus Vaccine Compositions and Methods of Using Thereof
09/16/2010US20100233205 Adjuvanted antigenic meningococcal compositions
09/16/2010US20100233204 Immunogenic Compositions and Methods for Treating and Preventing Animal Infections
09/16/2010US20100233203 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against recombinant antigen in mva vaccines
09/16/2010US20100233202 Novel viral vector
09/16/2010US20100233201 Vaccine composition
09/16/2010US20100233200 Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
09/16/2010US20100233199 Modulators of hypersensitivity reactions
09/16/2010US20100233198 Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
09/16/2010US20100233197 Method for generating tolerogenic dendritic cells employing decreased temperature
09/16/2010US20100233196 Method for preparing a vaccine composition comprising at least one antigen and at least one adjuvant
09/16/2010US20100233195 Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
09/16/2010US20100233194 Treatment of neovascular ocular disease states
09/16/2010US20100233193 Systemic administration of nac for vaccination prophylaxis
1 ... 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 ... 1823